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Context: Polycystic ovary syndrome (PCOS) is associated with increased psychological distress,
obesity and hyperandrogenism being suggested as key promoters.
Objectives: To investigate the prevalence of anxiety/depression and their coexistence in women
with PCOS/PCOS-related symptoms at ages 31 and 46. The roles of obesity, hyperandrogenism, and
awareness of PCOS on psychological distress were also assessed.
Design: Population-based follow-up.
Setting: Northern Finland Birth Cohort 1966 with 15-year follow-up.
Participants: At age 31, a questionnaire-based screening for oligoamenorrhea (OA) and hirsutism
(H): 2188 asymptomatic (controls), 331 OA, 323 H, and 125 OA plus H (PCOS). Follow-up at age 46:
1576 controls, 239 OA, 231 H, and 85 PCOS.
Interventions: Questionnaire-based screening for anxiety and depression symptoms (Hopkins
Symptom Checklist-25) and previously diagnosed/treated depression at ages 31 and 46. Body
mass index (BMI), serum testosterone/free androgen index, and awareness of polycystic ovaries/
PCOS on psychological distress were also assessed.
Main Outcomes: Population-based prevalence of anxiety and/or depression in women with PCOS/
PCOS-related symptoms at ages 31 and 46.
Results: Anxiety and/or depression symptoms, their coexistence, and rate of depression were
increased at ages 31 and 46 in women with PCOS or isolated H compared with controls. High
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BMI or hyperandrogenism did not associate with increased anxiety or depression symptoms. The
awareness of PCOS was associated with increased anxiety.
Conclusions: Women with PCOS or isolated H present more often with anxiety and/or depression
symptoms and their coexistence compared with controls. High BMI or hyperandrogenism did not
provoke psychological distress in PCOS. The awareness of PCOS increased anxiety but did not
associate with severe anxiety or depression. (J Clin Endocrinol Metab 102: 1861–1869, 2017)
Polycystic ovary syndrome (PCOS) is often consideredas a reproductive and metabolic disorder, leaving the
possible psychological impact of the syndrome neglected.
Previous studies, however, present strong evidence of
women with PCOS having higher prevalence of psychi-
atric disorders and increased emotional distress (1–3). In
fact, many studies have shown the prevalence of anxiety
and depression being two to four or even eight times
higher in women with PCOS compared with controls
depending on the investigated population (1, 4–6). In
addition to anxiety and depression, the women with
PCOS also present with decreased body dissatisfaction
and low self-esteem (7). Alarmingly, as reported in a
recent study, although the emotional burden coincides
with PCOS, neither patients with PCOS nor general
practitioners consider psychological distress as one of the
key characteristics of PCOS, which might reflect un-
awareness of this common comorbidity (8).
Several factors have been suggested to promote
psychological distress in women with PCOS, including
infertility, high body mass index (BMI), metabolic dis-
orders, and symptoms of hyperandrogenism (5, 9, 10),
although some studies suggest an independent effect of
PCOS even after controlling for some of these factors (11,
12). Concerning isolated PCOS symptoms, persisting
hirsutism (H) is known to be associated with low self-
esteem, social anhedonia, depression, and anxiety. Lack
of effective treatment burdens the women further (13, 14).
So far, only few data exist on the effect of isolated
menstrual disorders on psychological distress outside the
context of menopause, and only few data exist on the role
of consultation and awareness of the syndrome on anxiety
and depressive symptoms.
Most of the previously conducted studies assessing
psychological distress in women with PCOS have been
small and have included mostly women of reproductive
age. The studies have also been lacking a population-
based approach and/or follow-up. The current study used
the Northern Finland birth cohort 1966 (NFBC1966),
a unique longitudinal data set comprising follow-up
of all individuals with expected birth in 1966 in the
Northern Finland area (5889 females). Women with
PCOS are identified in this data set with two simple
questions on oligoamenorrhea (OA) and excessive
hair growth (H) also allowing evaluation of isolated
PCOS symptoms; oligoamenorrhea (OA) or H (15–17).
The NFBC1966 features the longest population-based
46-year-old follow-up in women with PCOS, and it
includes extensive data collection and clinical mea-
surements at fertile age (age 31) and at premenopause
(age 46).
The first aim of the study was to screen for mental
disorders, anxiety, and depression and their coexistence
in women with formally diagnosed PCOS or PCOS-
related symptoms (H and OA) at ages 31 and 46. Sec-
ond, we evaluated the role of obesity and biochemical
hyperandrogenism on psychological distress in women
with PCOS symptoms. The third aim was to investigate
the effect of PCOS awareness on psychological distress.
Materials and Methods
Study population
The NFBC1966 population consists of all individuals in
Northern Finland with expected birth in 1966 (total, N =
12,058; females, n = 5889), representing 96.3% of all births in
this region (18). After birth, there have been four follow-up time
points at ages 1, 14, 31, and 46 years; this study utilizes the two
latter ones (Fig. 1). During both of these time points, the data
were gathered by sending a questionnaire to all cohort subjects
Figure 1. Flowchart of the study population in the NFBC1966.
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and by inviting them to clinical examinations. The questionnaire
was sent to all 5608 women (alive and address known) in the
cohort at age 31 (1996 to 1997), and from these, 4523 (81%)
responded. The questionnaire included questions on weight and
height and questions screening for PCOS symptoms: (1) Is your
menstrual cycle longer than 35daysmore than twice a year (OA)?
(2) Do you have excessive body hair (H)? Of all women, 10.9%
reported H, 10.8% OA, 24.8% H and/or OA, and 3.4% both
symptoms (considered PCOS). The hormonal and metabolic
characteristics at ages 31 and 46 have been reported previously
(15–17). The women who were pregnant or using hormonal
contraceptives were excluded from the final study population.
Thus, the final analysis at age 31 consisted of 2188 asymptomatic
women (considered as controls), 331 (11.2%) women with OA,
323 (10.9%)womenwithH, and125 (4.2%)with PCOS (Fig. 1).
Clinical examinations [including measurements for weight,
height, serum testosterone (T), and free androgen index (FAI)]
were performed in 3127 (76%) women.
The questionnaires regarding psychological outcomes and
the clinical examination (including samemeasurements as at age
31) were replicated in 2013 when the participants were 46 years
old. The questionnaire was sent to 5123 women (alive and
address known) with an answer rate of 72% (n = 3760).
Furthermore, 3280 (64%) women participated in the clinical
examinations. The flowchart of the study subjects is presented in
Fig. 1. The study was approved by the Ethics Committee of the
Northern Ostrobothnia District. All participants provided an
informed consent.
Methods
Hopkins’ Symptom Check List-25
Psychological distress was assessed using the Hopkins
Symptoms Checklist-25 (HSCL-25) both at ages 31 and 46.
This symptom inventory is a well-known and widely used
screening instrument for anxiety and depression; part 1 in-
cludes 10 items for anxiety symptoms, and part 2 includes 15
items for depression symptoms (19, 20). The scale varies be-
tween 1 and 4: 1 = not bothersome and 4 = extremely both-
ersome. The total score is the average of all 25 items and has
been consistently shown to be highly correlated with severe
emotional distress of unspecified diagnosis (19, 20). The
questions are also separated for screening anxiety or de-
pression symptoms. Commonly used cutoff points are $1.55
and $1.75, the latter one most likely indicating a psychiatric
disorder (21, 22).
Self-reported diagnosis for depression set
by a physician
The history for previously diagnosed depression or de-
pressive symptoms was assessed by posing a question: “Have
you ever been diagnosed with/treated for depression/depressive
symptoms by a physician?” The answer options were “yes” or
“no.” The question was included in both 31- and 46-year-old
questionnaires.
PCOS awareness
At the age of 46, a questionnaire regarding PCOS awareness
of the subjects was assessed by posing a question: “Have you ever
been diagnosed as having polycystic ovaries and/or PCOS?”
Confounding variables
BMI
In the clinical examinations, participants’ weights (kg) were
measured on a digital scale that was calibrated regularly. Height
(cm) was measured two times by using standard and calibrated
stadiometer. BMI was calculated (kg/m2) by using measured
height (average of two measurements) and weight. When the
measurement was missing, the self-reported values were used.
No statistical difference was observed between the measured
and the self-reported BMIs (17).
T and FAI
At ages 31 and 46, sex serum T (17) and sex hormone-
binding globulin (SHBG) (15) were assayed as previously de-
scribed. Briefly, T was assayed using Agilent triple quadrupole
6410 liquid chromatography/mass spectrometry equipment
with an electrospray ionization source operating in positive-ion
mode (Agilent Technologies, Santa Clara, CA). The SHBG was
assayed by chemiluminometric immunoassay (Immulite 2000;
Siemens Health Care, Llanberis, UK). There was a level dif-
ference in the assays from different time points; therefore, the
values at age 31 were amended as follows: 0.7615 3 (SHBG at
age 31) + 0.7088. The FAI was calculated by using the equation
100 3 T (nmol/L)/SHBG (nmol/L). The biochemical hyper-
androgenism was established by using the highest T quartiles at
ages 31 and 46.
Socioeconomic status
Socioeconomic status was based on education. The variable
was classified into three groups by the number of education
years: 9 years, between 9 and 12 years, and more than 12 years.
Statistical analysis
The statistical analyses were performed using SPSS system
version 22 for Windows. The HSCL-25 scores were analyzed
using the Kruskal-Wallis H-test and with posthoc analyses. The
changes of the HSCL-25 after 15-years were analyzed using the
Wilcoxon test. To estimate the risk related to PCOS symptoms
and increased psychological distress univariate or multivariate
logistic regression models we used. Categorical variables and
HSCL-25 cut-offs were analyzed using the x2 test. The results
are reported as medians (25% and 75% quartiles), prevalence
(%), and odds ratios (OR) with 95% confidence interval (CI).
The logistic regression analysis was also done as covariate
analysis including BMI or T in the analysis. For calculating T/
FAI correlations, the Spearman correlationwas used.P values,
0.05 were considered as statistically significant. There were no
differences between the groups in primary education; thus it was
not included in the adjustment analysis.
Results
The women with PCOS presented with an increased
rate of anxiety and/or depression symptoms beyond
fertile age
HSCL-25 anxiety
TheHSCL-25median anxiety scorewas higher in both
the PCOS and the H groups at ages 31 and 46 compared
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with controls (31 years: P , 0.001; 46 years: P = 0.002)
(Table 1). Regarding the severity of the symptoms, at age
31, the number of women with anxiety score $1.75 was
almost double in both PCOS and H groups compared
with that of controls (16.1% and 16.1% vs 8.2%, P ,
0.001) (Table 1). At age 46, however, only the H group
showed more women with score $1.75 compared with
controls (14.8% vs 8.3%, P = 0.006).The OA group did
not differ from controls in anxiety symptoms. As for
longitudinal analysis, only in theH groupwas the anxiety
score decreased slightly but significantly during the
follow-up from age 31 to 46 (P = 0.024), although the
median anxiety scores were similar between the PCOS
and H groups at ages 31 and 46.
HSCL-25 depression
Similar to anxiety, the PCOS and H groups also pres-
ented with more depression-related symptoms compared
with controls at age 31 (HSCL-25 mean depression score:
P, 0.001), but only theHgroup had a significantly higher
depression score at age 46 (1.33 vs 1.27, P , 0.001)
(Table 1). The number of womenwith PCOS or isolatedH
having a depression score $1.75 was increased compared
with controls at age 31 (19.4% and 17.6% vs 12.7%, P,
0.001), but the difference was significant only in the H
group at age 46 (23.3% vs 15.2%, P = 0.013). Interest-
ingly, the OA group also had an increased depression
median score at age 31 (P , 0.001) (Table 1), but the
difference was abolished at age 46.
The prevalence of depression diagnosis by
premenopause is more common in women with
PCOS or isolated H than in controls
The women with PCOS or isolated H reported being
diagnosed or treated for depression symptomsmore often
than controls both at age 31 (9.6% and 9.0% vs 5.3%,
P = 0.003) and 46 (25.9% and 20.0% vs 14.0%, P =
0.003) [Fig. 2(a)]. In the logistic regression analysis, the
risk for reporting depression between ages 31 and 46 was
increased significantly only in the PCOS group compared
with controls [OR (CI): 1.97 (1.13 to 3.45)] [Fig. 2(b)].
The role of BMI, T, and FAI on anxiety and depression
symptoms and on the risk for reporting depression
BMI
The HSCL-25 anxiety and depression scores were
also analyzed in different BMI groups: ,25 kg/m2, 25
to,30 kg/m2, or$30 kg/m2 (Supplemental Table 1). At
age 31, among obese women, no differences in anxiety
scores were found between the different study groups.
Interestingly, the women with PCOS or isolated H with a
BMI ,25 kg/m2 or 25 to ,30 kg/m2 had significantly
higher anxiety scores compared with controls, showing
that obesity was not a major contributor (Supplemental
Table 1), and this was also the case with depression. In
fact, the depression scores inwomenwith aBMI,25kg/m2
were higher in PCOS and H groups compared with
controls. Only in the H group at age 46 were the anxiety
Table 1. HSCL-25 Median Score (25% to 75% Quartiles) and Number (%) of Women With HSCL-25 Score
Cutoff ‡1.75
HSCL-25 Age, y Ctrl OA H PCOS P Valuea
31 (n = 2187) (n = 330) (n = 323) (n = 124)
46 (n = 1618) (n = 247) (n = 236) (n = 86)
Anxiety median score
31 1.20 (1.10–1.40) 1.30 (1.10–1.50) 1.32 (1.20–1.60)b,c 1.30 (1.20–1.60)b ,0.001
46 1.20 (1.10–1.40) 1.20 (1.10–1.40) 1.30 (1.10–1.50)b 1.30 (1.11–1.60)b 0.002
Anxiety score $1.75
31 8.2% 7.6% 16.1%b 16.1%b ,0.001
46 8.3% 7.7% 14.8%b 12.8% 0.006
Depression median score
31 1.27 (1.33–1.53) 1.33 (1.33–1.60)b 1.40 (1.20–1.67)b 1.40 (1.15–1.67)b ,0.001
46 1.27 (1.07–1.59) 1.27 (1.13–1.53) 1.33 (1.13–1.73)b 1.27 (1.12–1.62) 0.040
Depression score $1.75
31 12.7% 15.8% 17.6%b 19.4%b 0.015
46 15.2% 14.6% 23.3%b 17.4% 0.013
Total median score
31 1.28 (1.12–1.48) 1.32 (1.16–1.52)b 1.36 (1.20–1.60)b 1.40 (1.20–1.60)b ,0.001
46 1.28 (1.12–1.48) 1.28 (1.12–1.48) 1.32 (1.16–1.60)b 1.28 (1.16–1.60) 0.011
In control women and women with PCOS/PCOS-related symptoms. Population-based follow-up analysis at ages 31 and 46.
Abbreviation: Ctrl, control.
aP , 0.05 between the different study groups at ages 31 or 46.
bP , 0.05 compared with controls.
cP , 0.05 between ages 31 and 46 in the same group.
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and depression scores higher in obese women com-
pared with women of a BMI ,25 kg/m2 (Supplemental
Table 1).
In the logistic regression analysis, the risk inwomenwith
PCOS self-reporting depression diagnosis between age ages
31 and 46 was higher than in controls, even after adjusting
for BMI [OR (CI): 2.02 (1.12 to 3.64)] [Fig. 2(b)].
T and FAI
There was no significant correlation between HSCL-
25 anxiety or depression scores with T/FAI at age 31 or
46 (Fig. 3). The anxiety and depression scores were not
higher in the upper T and FAI quartiles between the study
groups. In fact, the highest FAI quartile showed decreased
anxiety in PCOS and decreased depression scores in
women with isolated H (Supplemental Table 2). Alto-
gether, biochemical hyperandrogenism was not associ-
ated with high anxiety or depression scores at age 31 or
46 (Supplemental Table 2).
Coexistence of anxiety and depression in women
with PCOS symptoms
Both in the PCOS and the H groups, the coexistence
of anxiety and depression was more common than in
controls at age 31 and/or 46 (31 years: 11.3% and 9.9%
vs 5.2%, P, 0.001; 46 years: 9.3% and 12.3% vs 6.1%,
P = 0.002) [Fig. 4(a)]. Accordingly, the risk for coexisting
anxiety and depression was also increased in PCOS and
H groups [31 years: 2.43 (1.34 to 4.39), 2.12 (1.40 to
3.21); 46 years: 1.61 (0.75 to 3.44) and 2.26 (1.45 to
3.53)] [Fig. 4(b)]. BMI was shown to be a weak in-
dependent risk factor in the regression analysis, and
PCOS and H remained as independent risk factors after
the adjustment. Biochemical hyperandrogenism was not
an independent risk factor.
PCOS awareness related to increased psychological
distress at age 46
Thewomenwith bothH andOA symptoms (PCOS) at
age 31 were asked about their awareness of having PCOS
at age 46. Interestingly, there were more women with a
higher anxiety score (HSCL-25. 1.55) who were aware
of their diagnosis compared with the ones not aware
(42.3% vs 20%, P = 0.032), and a similar trend was also
shown in depression (38.5% vs 21.7%, not significant)
(Fig. 5). On the other hand, awareness did not associate
Figure 2. (a) Prevalence (%) of self-reported diagnosis for
depression by ages 31 and 46 in control women (Ctrl, n = 2177)
and in women with OA (n = 248), H (n = 235), or PCOS (n = 85) in
a population-based follow-up analysis. At age 31, the prevalence of
self-reported diagnosis for depression was higher in H and PCOS
groups when compared with controls. By age 46, the women with
H and PCOS presented with higher prevalence of depression
compared with controls (*P , 0.05, **P , 0.01). (b) The risk for
newly diagnosed depression between ages 31 and 46 [OR (95%
CI)]. Crude analysis and adjustments for BMI (at age 31 and change
from 31 to 46) and T. The risk for newly diagnosed depression
between ages 31 and 46 was increased in women with PCOS
[crude OR: 1.97 (1.13 to 3.45), BMI-adjusted OR: 2.02 (1.12 to
3.64), and T-adjusted OR: 2.17 (1.31 to 3.59)].
Figure 3. Spearman correlation between serum T and FAI and HSCL-25 anxiety or depression scores at ages 31 and 46. No significant
correlation was found between the hormonal measurements and psychological distress scores.
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with severe depression or anxiety (HSCL-25 . 1.75)
(Fig. 5).
Women who dropped out by age 46 had increased
psychological distress at age 31
After 31-year-old data collection, 578 controls, 83
OA, 86 H, and 39 PCOS were lost in the follow-up
(dropouts). The dropout rate varied between 27% and
39% and tended to be higher in the PCOS group com-
pared with controls (data not shown). The number of
depression diagnoses at age 31 was higher in the dropout
H group and controls compared with the women who
stayed in the follow-up until age 46, and a similar trend
was also observed in the PCOS group (H: 14.8% vs
6.8%, P = 0.026; control: 7.8% vs 4.4%, P = 0.002;
PCOS: 17.5% vs. 5.9%, P = 0.053).
Discussion
To our knowledge, this study provides the longest follow-
up data (reaching up until premenopausal age) assessing
anxiety and depression in women with PCOS/PCOS-
related symptoms. The results reveal that the women with
PCOS, screened with two simple questions on menstrual
irregularities and excessive hair growth or women
reporting isolated H, experienced increased anxiety
and/or depression symptoms up until premenopausal
age. Also the coexistence of anxiety and depression
seemed to be more prevalent in PCOS compared with
controls. PCOS was shown to have an independent
effect on psychological distress, whereas high BMI or
biochemical hyperandrogenism were not significant
contributors for more prevalent anxiety or depression
symptoms. OA alone was not associated with severe
psychological distress.
Previous studies have reported high risk for a range of
psychiatric disorders in women with PCOS (1, 2, 23).
Nevertheless, the majority of previous studies have in-
cluded a selected PCOS population, mostly including
women of reproductive age. In the present nonselected
population-based data, at age 31, the prevalence of anxiety
was twice as high in women with PCOS compared with
controls. This is in line with a previously published Danish
register study (1) but somewhat higher than in a recent
Swedish study (23). Alarmingly, the overall anxiety score
was higher at age 46 in women with PCOS compared with
controls, suggesting that the stress-related symptoms seem
to persist up until premenopausal age in these women.
H has been shown to have a negative impact on self-
esteem with decreasing quality of life (24, 25), and in
many cases, the available treatments remain insufficient
(26). In the current study, isolated H also associated with
high anxiety scores similar to PCOS. Furthermore, the
mean scores remained higher up until premenopausal age
in this group, suggesting that H is a major burden to
women and underlying the need for effective treatments.
Similar to present results, previous studies have also
shown a high rate of depression in women with PCOS (1,
5, 11, 23). TheHSCL-25 depression scores were higher in
PCOS compared with controls at age 31; however, the
difference was attenuated by age 46. It is likely that
dropouts had some effect on this because, in the dropout
analysis, the women not participating in 46-year-old
follow-up had increased depression symptoms com-
paredwith nondropout PCOSwomen and controls at age
31. Nevertheless, 25% of women with PCOS reported
being diagnosed for depression or depressive symptoms
by age 46, whereas the respective prevalence was only
14% for the controls. The prevalence of depression in
controls is in line with the data from the United States
showing a depression rate of 12.3% in the general female
population from ages 40 to 59 (27). Interestingly, the risk
for being newly diagnosed with depression between ages
31 and 46 was also increased in PCOS. The present data
also reveal that the risk for coexistence of anxiety and
depression in PCOS is about twofold compared with
women without PCOS symptoms.
Figure 4. (a) The prevalence (%) of coexistence of anxiety and
depression symptoms using HSCL-25 cutoff $1.75 at ages 31 and
46 in control (Ctrl) women and in women with OA, H, or PCOS. At
age 31, the prevalence of coexistence was higher in H and PCOS
groups. At age 46, only in the H group was the coexistence higher
than in the controls, although a similar trend was also shown
in the PCOS group (**P , 0.01, ***P , 0.001). (b) The risk
[OR (95% CI)] for coexistence of HSCL-25 anxiety and depression
using cutoff $1.75 in the OA, H, and PCOS groups. At age 31, the
risk was higher in H [OR: 2.12 (1.40 to 3.21)] and PCOS groups
[OR: 2.43 (1.34 to 4.39)]. At age 46, only the H group reached
significance [OR: 2.26 (1.45 to 3.53)].
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The data also show that self-reported isolated H is
associated with a surprisingly high prevalence of clini-
cally significant depression score compared with controls
(20% vs 14%). Previous studies have shown association
between excessive hair growth and depression (5, 28).
In a recent study, H scores using the Ferriman Gallwey
scale, set by a physician and women with PCOS, were
compared and revealed scores that were 4.6 points higher
in self-reported cases, underlying the discordance of H
scoring between doctors and patients (13). Interestingly,
only self-reported scores were significantly associated
with depression. These findings underline the difficulty of
objective scoring of H due to commonly used epilation
but also suggest that the subjective perception of H
should also be considered as an important and useful tool
in clinical practice.
Although BMI has been suggested as one of the major
contributors to psychological distress in women with
PCOS (5), this was not the case in our population in
which high BMI was not associated with increased
anxiety or depression. The discrepancy between our re-
sults and those of previous studies could be due to our
population-based approach but also due to the fact that
the mean BMI in the PCOS group was relatively low in
the current study compared with studies in the United
States or Australia (11, 29), although it was comparable
with studies performed in Turkey (5).
As for biochemical hyperandrogenism, similar to BMI,
it did not seem to be an explanatory factor in the analysis
as no correlation was found between high T or FAI levels
and psychological distress scores. In fact, similar to a
previous study, high FAI was related to a lower anxiety
score in women with PCOS (12) and a lower depression
score in women with isolated H. However, the H group
having similar psychological distress to the PCOS coun-
terparts may imply that the distress in both groups was at
least partly related to skin manifestations, although the
role of biochemical hyperandrogenism may not be
completely ruled out. For example,
exposure to hyperandrogenism in
the perinatal period may have an ef-
fect on brain development without
affecting circulating androgen levels
in adulthood, the mechanisms most
likely being multifaceted and com-
plex. Indeed, a recent study suggested
hyperandrogenism as one of the mech-
anisms behind anxiety and depression
in a PCOS ratmodel inwhich prenatally
androgenized rats showed anxiety-like
behavior as adults without differences
in circulating androgen levels (30).
Furthermore, some indirect androgen-
related/mediated mechanisms such as increased sym-
pathetic nervous system activity, insulin resistance, and
inflammation might also be involved (31–34), and the
synergistic role of hyperandrogenism in these cases pro-
moting psychological stress still warrants further studies
in humans.
Clinicians have been debating whether giving a formal
diagnosis of PCOS will itself cause psychological distress
in women. In our study, PCOS awareness by age 46 was
related to increased prevalence of anxiety symptoms but
not severe anxiety or depression. This is in line with a
recent study showing increased psychological distress in
youngwomen after establishing the PCOS diagnosis (35).
These findings support the need for counseling in all cases
as well as fostering a positive, multidisciplinary health
care environment.
The current study has several strengths but also some
limitations. This unique population-based data set shows
that, with two simple questions, we were able to identify
a female population with a high risk of psychological
distress. Furthermore, previous population studies have
few or no data on psychological distress in women with
isolated PCOS symptoms. Because the data collection did
not specifically target PCOS, the self-aware bias wasmost
likely low compared with selected PCOS populations
from endocrine or infertility clinics or hospital registers.
The questionnaires also screened symptoms for mental
distress and not only diagnoses in hospital registers, thus
also including milder cases. This data also represent the
assessment of the oldest group of women with PCOS for
these psychological outcomes, including only women
at similar age, ethnicity, and geographic location. The
clinicalmeasurements were adjusted for several variables:
socioeconomic status, BMI, and T/FAI. On the other hand,
the limitations include self-reported PCOS diagnosis, al-
though the validity of the PCOS diagnosis has been pre-
viously published (16, 17). The diagnosis of previously
diagnosed/treated depression was also self-reported, but
Figure 5. The effect of awareness of PCOS diagnosis by age 46 and the prevalence (%) of
HSCL-25 anxiety and depression symptoms at age 46 using cutoffs $1.55 and $1.75. The
prevalence of anxiety symptoms (HSCL-25 $ 1.55) was higher in women who were aware of
the PCOS diagnosis by age 46 (42.3% vs 20.0%, P = 0.032). The awareness did relate to
severe anxiety or depression (HSCL-25 $ 1.75).
doi: 10.1210/jc.2016-3863 https://academic.oup.com/jcem 1867
again, previous studies have reported similar prevalence
in control populations. Despite the low dropout rate in
general, it still had some impact on the results, as the
women not participating in the 46-year-old follow-upwere
the ones with a higher rate of psychological distress at
age 31.
In conclusion, women with PCOS present with in-
creased symptoms of anxiety and depression and co-
existence of these morbidities until premenopausal age,
thus raising the need for screening for these symptoms in
clinical practice. It should be noted that providing a di-
agnosis, and thereby increasing PCOS awareness in pa-
tients, may promote anxiety, emphasizing that a positive
and supportive health care environment is warranted.
Further studies should be aimed at establishing the mech-
anism behind psychological distress in PCOS.
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